In this special year-end episode of Moving Medicine Forward, host Jeremy Schrand sits down with CTI’s founder and CEO Tim Schroeder and President & COO Jon Koch for an in-depth look at 2025. From strategic goals and operational breakthroughs to cultural pillars and global challenges, Tim and Jon share candid insights on what made this year transformative for CTI. They also discuss major clinical milestones, regulatory shifts, and the innovations shaping the future—including AI, patient-centric trial design, and advanced therapies. Whether you’re a team member, sponsor, or industry partner, this conversation offers a front-row seat to the trends and strategies driving the next era of clinical research.

00:36 Tim Schroeder and Jon Koch join for a candid discussion on CTI’s journey through 2025.

01:00 Strategic goals, clinical milestones, and cultural highlights that defined the year.

01:39 Tim reflects on CTI’s long-term vision, process improvements, and technology adoption.

02:58 Balancing analytics-driven growth with personal and professional development.

04:00 Jon shares key initiatives—integrating clinical, site, and lab capabilities; EMA’s adoption of ICH E6(R3).

05:33 Nearly 20 successful approvals over two years underscore CTI’s mission.

06:08 Navigating new clients, acquisitions, and global disruptions while maintaining quality.

07:17 How CTI adapted to FDA leadership changes and global health trends.

11:38 Care, persistence, and community engagement as defining traits of CTI’s global team.

14:34 Persistence and stability in an industry with high stakes and long timelines.

17:08 Priorities include ICH E6(R3) implementation, global expansion, and AI-driven innovation.

20:22 Building the strongest management team for CTI’s next quarter-century.

22:03 Tim and Jon share messages of thanks and confidence in the future of medicine.

25:15 CTI’s commitment to advancing medicine and fostering a culture of care and resilience.